title: Abnormal iron homeostasis and neurodegeneration.
abstract: Abnormal iron metabolism is observed in many neurodegenerative diseases, however, only two have shown dysregulation of brain iron homeostasis as the primary cause of neurodegeneration. Herein, we review one of these - hereditary ferritinopathy (HF) or neuroferritinopathy, which is an autosomal dominant, adult onset degenerative disease caused by mutations in the ferritin light chain (FTL) gene. HF has a clinical phenotype characterized by a progressive movement disorder, behavioral disturbances, and cognitive impairment. The main pathologic findings are cystic cavitation of the basal ganglia, the presence of ferritin inclusion bodies (IBs), and substantial iron deposition. Mutant FTL subunits have altered sequence and length but assemble into soluble 24-mers that are ultrastructurally indistinguishable from those of the wild type. Crystallography shows substantial localized disruption of the normally tiny 4-fold pores between the ferritin subunits because of unraveling of the C-termini into multiple polypeptide conformations. This structural alteration causes attenuated net iron incorporation leading to cellular iron mishandling, ferritin aggregation, and oxidative damage at physiological concentrations of iron and ascorbate. A transgenic murine model parallels several features of HF, including a progressive neurological phenotype, ferritin IB formation, and misregulation of iron metabolism. These studies provide a working hypothesis for the pathogenesis of HF by implicating (1) a loss of normal ferritin function that triggers iron accumulation and overproduction of ferritin polypeptides, and (2) a gain of toxic function through radical production, ferritin aggregation, and oxidative stress. Importantly, the finding that ferritin aggregation can be reversed by iron chelators and oxidative damage can be inhibited by radical trapping may be used for clinical investigation. This work provides new insights into the role of abnormal iron metabolism in neurodegeneration.
authors.affiliation: Department of Chemistry and Chemical Biology, Indiana University-Purdue University Indianapolis Indianapolis, IN, USA.
authors.forename: Barry B
authors.initials: BB
authors.lastname: Muhoberac
authors.forename: Ruben
authors.initials: R
authors.lastname: Vidal
keywords: ferritin; inclusion bodies; iron; neurodegeneration; neuroferritinopathy; oxidative stress
references.citation: Free Radic Biol Med. 2013 Sep;62:76-89
references.pmid: 23142767
references.citation: Neurosci Lett. 2010 Jul 19;479(1):44-8
references.pmid: 20478358
references.citation: J Biol Chem. 1992 Jul 15;267(20):14077-83
references.pmid: 1629207
references.citation: Brain. 2007 Jan;130(Pt 1):110-9
references.pmid: 17142829
references.citation: Free Radic Biol Med. 2012 May 1;52(9):1692-7
references.pmid: 22348978
references.citation: Neuroscientist. 2011 Aug;17(4):389-406
references.pmid: 21666063
references.citation: Top Magn Reson Imaging. 2006 Feb;17(1):5-17
references.pmid: 17179893
references.citation: Brain. 2009 Jun;132(Pt 6):e109
references.pmid: 18854324
references.citation: J Neuropathol Exp Neurol. 2005 Apr;64(4):280-94
references.pmid: 15835264
references.citation: Neurology. 2005 Aug 23;65(4):603-5
references.pmid: 16116125
references.citation: J Neurol Neurosurg Psychiatry. 1997 Aug;63(2):196-203
references.pmid: 9285458
references.citation: Mov Disord. 2009 Aug 15;24(11):1676-83
references.pmid: 19514068
references.citation: J Neurochem. 2009 May;109(4):1067-78
references.pmid: 19519778
references.citation: J Biol Chem. 1984 Mar 25;259(6):3620-4
references.pmid: 6323433
references.citation: Neurology. 2008 Apr 15;70(16 Pt 2):1493-4
references.pmid: 18413574
references.citation: Biochim Biophys Acta. 2010 Aug;1800(8):706-18
references.pmid: 20363295
references.citation: FEBS J. 2006 Dec;273(23):5428-41
references.pmid: 17116244
references.citation: Mol Neurodegener. 2010 Nov 10;5:50
references.pmid: 21067605
references.citation: J Biol Chem. 2010 Jan 15;285(3):1950-6
references.pmid: 19923220
references.citation: Neurology. 2008 Apr 29;70(18):1614-9
references.pmid: 18443312
references.citation: J Neuropathol Exp Neurol. 2004 Apr;63(4):363-80
references.pmid: 15099026
references.citation: J Neurosci. 2008 Jan 2;28(1):60-7
references.pmid: 18171923
references.citation: Nature. 2006 Oct 19;443(7113):774-9
references.pmid: 17051203
references.citation: J Neuropathol Exp Neurol. 2004 Aug;63(8):787-800
references.pmid: 15330334
references.citation: Nat Genet. 2001 Aug;28(4):350-4
references.pmid: 11438811
references.citation: Mov Disord. 2009 Feb 15;24(3):441-5
references.pmid: 19117339
references.citation: Cell Metab. 2011 Apr 6;13(4):361-366
references.pmid: 21459321
references.citation: Acta Neuropathol. 2005 Jan;109(1):109-14
references.pmid: 15645266
references.citation: J Biol Chem. 1993 Jun 15;268(17):12744-8
references.pmid: 8509409
references.citation: Nat Rev Neurosci. 2004 Nov;5(11):863-73
references.pmid: 15496864
references.citation: Biochim Biophys Acta. 2011 Apr;1812(4):544-8
references.pmid: 21029774
references.citation: J Biol Chem. 2008 Nov 14;283(46):31679-89
references.pmid: 18755684